Xeomin in the treatment of poststroke spasticity

Khat’kova S.E.

Federal state budgetary institution «Medical and Rehabilitation Center», Moscow

Authors:

Khat’kova S.E.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(8): 62‑64

Downloaded: 9

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Khat’kova SE. Xeomin in the treatment of poststroke spasticity. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(8):62‑64. (In Russ.)

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)

Close metadata

Keywords:

poststroke spasticity

treatment

xeomin

Authors:

Khat’kova S.E.

Federal state budgetary institution «Medical and Rehabilitation Center», Moscow

List of references:

Bakheit M. Botulinum toxin treatment of muscle spasticity. 2nd ed. AuthorHouse 2007; 216.
Barnes M., Schnitzler A., Amaral e Silva A. et al. NT 201 (Xeomin; botulinum neurotoxin free from complexing proteins) is efficacious and well-tolerated in upper limb spasticity of various etiologies. Abstracts of the Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders, Paris, 7-11.06.09. Mov Dis 2009; 24 (Suppl 1): S450.
Barnes M., Schnitzler A., Medeiros L. et al. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies - a randomized parallel-group study. Acta Neurol Scand DOL: 10.1111/j.1600-0404.2010.01354.x. The Authors Journal compilation 2010 Blackwell Munksgaard.
Benecke R., Jost W.H., Kanovsky P. et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64: 1949-1951.
Bhakta B., Cozens J., Chamberlain M., Bamford J. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randimised double blind placebo controlled trial. J Neurol Neurosurg Psychiat 2000; 69: 2: 217-221.
Brashear A., Gordon M.F., Elovic E., Kassicieh V.D. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002; 347: 6: 395-400.
Childers M.K., Brashear A., Josefczyk P. et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004; 85: 1063-1069.
Dressler D., Hallett M. Immunological aspects of Botox, Dysport and Myobloc/Neurobloc. Eur J Neurol 2006; 16 (Suppl 1): S11-S15.
Dressler D., Mander G.J., Fink K. Equivalent potency of Xeomin and Botox. Mov Dis 2008; 23 (Suppl 1): S20-S21.
Dressler D. Comparing of Botox and Xeomin for axillar hyperhudrosis.
Francisco G.E. Botulinum toxin for post-stroke spastic hypertonia: a review of its efficacy and application in clinical practice. Ann Acad Med Singapore 2007; 36: 22-30.
Jankovic J. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol 2009; 16: 2: 14-18.
Jankovic J., Albanese A., Atassi M.Z. et al. Botulinum toxin: therapeutic clinical practice and science. Saunders 2009; 512.
Jost W.H., Kohl A., Brinkmann S. et al. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (Botox) in healthy volunteers. J Neural Transm 2005; 112: 905-913.
Jost W.H., Bluemel J., Grafe S. Botulinum neurotoxin type A free of complexing proteins (Xeomin) in focal dystonia. Drugs 2007; 67: 669-683.
Jost W., Valerius K.-P. Pictorial atlas of botulinum toxin injection: dosage, localization, application. Quintessence Pub Co 2008: 264.
Kanovsky P. et al. Efficasy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Mov Dis 2009; 24 (Suppl 1): S452.
Kanovsky P., Slawek J., Denes Z. et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol 2009; 32: 5: 259-265.
Roggenkaemper P., Jost W.H., Bihari K. et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006; 113: 303-312.
Simpson D.M., Gracies J.-M., Graham H.K. et al. Assessment: Botulinum toxin for the treatment of spasticity (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 19: 1691-1698.
Upper motor neurone syndrome and spasticity: clinical management and neurophysiology (Cambridge Medicine). 2nd ed. Cambridge University Press 2008; 264.
Wissel J., Ward A.B., Erztgaard P. et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009; 41: 13-25.

Close metadata